



EDITED BY  
JOHN A. GOODFELLOW

# Understanding Medical Research

**THE STUDIES THAT SHAPED MEDICINE**

 **WILEY-BLACKWELL**

# Contents

**Cover**

**Title Page**

**Copyright**

**Dedication**

**Contributors**

**Preface**

**Foreword**

**Acknowledgements**

**Chapter 1: Population Health**

**Introduction**

**Shoe-Leather Epidemiology**

**Smoking and Cancer: Association and Causality**

**The Inverse Care Law**

**Framingham and the Heart**

**The Evidence-Based Revolution**

**The Black Report**

**The Prevention Paradox**

**The Principles of Screening**

**Determining Causation**  
**On the State of Public Health**  
**Conclusion**  
**Key Outstanding Questions**  
**Key Research Centres**  
**References**

## **Chapter 2: Patient Safety**

**Introduction**  
**Florence Nightingale on Running a Hospital**  
**Codman and the End Results System**  
**Understanding the Prevalence of Medical Error**  
**Models for Understanding Error**  
**The Story of Wayne Jowett**  
**Setting the Agenda and Building Learning Organisations**  
**Technology and Patient Safety**  
**Hand Hygiene**  
**Standardising Care**  
**Using Checklists**  
**Conclusions**  
**Key Outstanding Questions**  
**Key Research Centres**  
**References**

## **Chapter 3: Heart Failure**

**Introduction**

**The Landmark Trial of Renin-Angiotensin Inhibition**

**The Multidisciplinary Heart Failure Team**

**An About-Turn in Medical Thinking: Beta-Blockers Are Good for Heart Failure**

**B-Type Natriuretic Peptide in Helping to Identify Heart Failure**

**The Digoxin Trial in Heart Failure Study**

**The Randomized Aldactone Evaluation (RALES) Study**

**Flogging a Dying Horse: The Sad Tale of Intravenous Inotropes**

**A Paradigm Shift: The Development of Cardiac Resynchronisation Therapy: CARE HF**

**Preventing Sudden Death by an Implantable Cardioverter Defibrillator**

**Telemonitoring: An Important Technological Advance in Monitoring Heart Failure**

**Key Outstanding Questions**

**Key Laboratories and Clinics**

**References**

**Additional References**

## **Chapter 4: Acute Coronary Syndrome (NSTEMI)**

**Introduction**

**Troponin: The Basis of Diagnosis**

**Aspirin: The Cornerstone of MI Management**

[\*The Additive Effect of Clopidogrel: A Case for Dual Anti-Platelet Therapy\*](#)  
[\*The New Kid on the Block: Fondaparinux\*](#)  
[\*Percutaneous Coronary Intervention: Who Should Get It?\*](#)  
[\*The Role of GPIIb/IIIa Inhibitors\*](#)  
[\*Use of ACE Inhibitors Post Myocardial Infarction: Dawn of a New HOPE\*](#)  
[\*Beta-Blockers: When to Give Them?\*](#)  
[\*Should All Post-MI Patients Get Statins?\*](#)  
[\*Aldosterone Antagonists\*](#)  
[\*Conclusion\*](#)  
[\*Key Outstanding Questions\*](#)  
[\*Key Research Centres\*](#)  
[\*References\*](#)

## [\*Chapter 5: Lipids, Dyslipidaemia and Cardiovascular Disease\*](#)

[\*Introduction\*](#)  
[\*The Beginnings of Clinical Lipidology: Fredrickson's Classification of Lipoprotein Phenotypes\*](#)  
[\*Dietary Saturated Fat and Cardiovascular Disease: The Seven Countries Study\*](#)  
[\*Risk Factors for Coronary Heart Disease: The Framingham Study\*](#)  
[\*Discovery of the LDL Receptor and the Cause of Familial Hypercholesterolaemia\*](#)  
[\*Recognition of the Protective Role of HDL against Cardiovascular Disease\*](#)



**The Discovery of Compactin: The First Statin**

**ApoE Polymorphism and Type III Hyperlipoproteinaemia**

**Role of the Scavenger Receptor in Atherosclerosis**

**Atheromatous Plaque Fissuring and Fatal Coronary Events**

**4S: The Trial That Proved the Lipid Hypothesis**

**Summary and Conclusions**

**Key Outstanding Questions**

**Key Research Centres**

**References**

## **Chapter 6: Atrial Fibrillation**

**Introduction**

**Basic Mechanisms: The Multiple-Wavelet Hypothesis**

**Basic Mechanisms: Wavelength**

**Basic Mechanisms: Pulmonary Veins**

**Basic Mechanisms: Mother Rotor**

**Atrial Remodelling: Atrial Tachycardia-Induced Remodelling**

**Atrial Remodelling: Congestive Heart Failure-Related Atrial Remodelling**

**Drug Therapy: Anticoagulation Therapy**

**Drug Therapy: Rhythm Control versus Rate Control**

**Drug Therapy: Upstream Therapy**

[Genetics](#)  
[Conclusions](#)  
[References](#)

## [Chapter 7: Asthma](#)

[Introduction](#)  
[The Pathophysiology of Asthma](#)  
[Treatment of Asthma](#)  
[Summary and Conclusions](#)  
[Key Outstanding Questions](#)  
[Key Research Centres](#)  
[References](#)

## [Chapter 8: Cystic Fibrosis](#)

[Introduction](#)  
[An Electrifying Finding: Abnormal Mucosal Potential Differences](#)  
[On the Shoulders of Giants: Chloride Permeability and CF](#)  
[Big Is Beautiful, and More Is Better](#)  
[A False Dawn? Finding the CF Gene](#)  
[Treatment of Respiratory Infection: The Early Bird Catches the Worm](#)  
[Many a Slip! The First Animal Model of CF](#)  
[No Such Thing as a Free Lunch: New Infections, New Problems](#)  
[Catch Them Early, Treat Them Quickly: A Randomised Controlled Trial of Screening for CF](#)

[\*Pathophysiology of CF: The Low-Volume Hypothesis\*](#)  
[\*A True Dawn? The Modern Era of Mutation Specific Therapies\*](#)  
[\*Summary and Conclusions\*](#)  
[\*Key Outstanding Questions\*](#)  
[\*Key Useful Websites\*](#)  
[\*References\*](#)

## [\*Chapter 9: Chronic Obstructive Pulmonary Disease\*](#)

[\*Introduction\*](#)  
[\*The Dutch Hypothesis\*](#)  
[\*Quantifying Lung Resistance in Small Airways Disease\*](#)  
[\*Assessing Decline in FEV<sub>1</sub>\*](#)  
[\*Exercise Training in COPD\*](#)  
[\*Supplementary O<sub>2</sub> Therapy in COPD\*](#)  
[\*Synchronised Smoking Cessation: Effect on Decline in FEV<sub>1</sub>\*](#)  
[\*Breathlessness and Dynamic Hyperinflation\*](#)  
[\*Effect of an Inhaled Steroid on FEV<sub>1</sub> Decline in Smokers with Mild COPD\*](#)  
[\*The Nature of Persistent Airway Inflammation in Ex-Smokers with COPD\*](#)  
[\*Small Airways Inflammation in COPD\*](#)  
[\*Exacerbations in COPD\*](#)  
[\*Summary and Conclusions\*](#)  
[\*Key Outstanding Questions\*](#)



**Key Research Centres**  
**References**

**Chapter 10: Pneumonia**

**Introduction**

**Prevention of Pneumonia - Vaccination  
against Streptococcus pneumoniae**

**Recognising the Patient with Pneumonia**

**Determining Where to Treat the Patient**

**Diagnosed with Pneumonia**

**Surviving Sepsis: Reducing the Mortality of  
Patients with Severe Pneumonia**

**Optimal Duration of Antibiotic Therapy**

**Sequelae of Pneumonia: Pleural Space  
Infection**

**Microbiology of Pneumonia**

**Novel Approaches to Diagnosing an  
Aetiological Cause of Pneumonia**

**Clustering of Pneumocystis jirovecii The  
First Presentation of the Acquired  
Immunodeficiency Syndrome (AIDS)**

**Legionnaires' Disease: an Epidemiological  
and Laboratory Mystery**

**Summary and Conclusions**

**Key Outstanding Questions**

**References**

**Chapter 11: Stroke**

**Introduction**

**Classifying Stroke by Aetiological Subtype**

**[The Brain Must Be Imaged Immediately after Arrival at Hospital](#)**

**[Stroke Units Save Lives](#)**

**[The First Definitive Drug Treatment for Acute Ischaemic Stroke](#)**

**[Hemicraniectomy Saves Lives in Malignant Cerebral Infarction without Increasing the Numbers of Severely Disabled Survivors](#)**

**[Secondary Prevention Should Start Early after Ischaemic Stroke](#)**

**[Preventing Recurrent Stroke in Those with Atrial Fibrillation](#)**

**[Preventing Recurrent Stroke in Those with Severe Carotid Artery Stenosis](#)**

**[Lowering Blood Pressure to Reduce the Risk of Recurrence after Stroke](#)**

**[Lowering Blood Lipids to Reduce the Risk of Recurrence after Stroke](#)**

**[Key Outstanding Questions](#)**

**[Key Research Centres](#)**

**[References](#)**

## **[Chapter 12: Parkinson's Disease](#)**

**[Introduction](#)**

**[Describing the Condition](#)**

**[Drug Treatments in Parkinson's Disease](#)**

**[Assessing Disease Severity](#)**

**[Developing Animal Models](#)**

**[Parkinson's Disease Surgery](#)**

**[Establishing the Diagnosis](#)**

[\*Motor Complications\*](#)  
[\*Redefining the Pathology\*](#)  
[\*Understanding the Genetics\*](#)  
[\*Summary\*](#)  
[\*Key Outstanding Questions\*](#)  
[\*Key Research Centres\*](#)  
[\*References\*](#)  
[\*Additional References\*](#)

## [\*Chapter 13: Epilepsy\*](#)

[\*Introduction and Historical Perspective\*](#)  
[\*The Birth of Anti-Epileptic Medication\*](#)  
[\*When to Begin Anti-Epileptic Medication?\*](#)  
[\*Which Anti-Epileptic Drugs to Start? The SANAD study\*](#)  
[\*Early Identification of Refractory Epilepsy\*](#)  
[\*Anti-Epileptic Drug Withdrawal\*](#)  
[\*Genetics and Epilepsy\*](#)  
[\*Impact of Epilepsy\*](#)  
[\*Anti-Epileptic Drugs and the Foetus\*](#)  
[\*Summary and Conclusions\*](#)  
[\*Key Outstanding Questions\*](#)  
[\*References\*](#)  
[\*Additional References\*](#)

## [\*Chapter 14: Motor Neuron Disease\*](#)

[\*Introduction\*](#)  
[\*The Recognition of ALS as a Disease of Two Compartments\*](#)

**Identification of the Pathological Hallmarks of MND**

**The First Gene in Familial MND**

**An Animal Model**

**The First Disease-Modifying Treatment**

**Identification of Clinical Prognostic Factors**

**Standardised Measurement of Disease**

**Progression and the Evolution of Clinical Trials**

**The Discovery of TDP-43**

**Understanding Focality and Spread of Pathology**

**Summary and Conclusion**

**Key Outstanding Questions**

**Key Research Centres**

**References**

**Additional References**

**Chapter 15: Migraine**

**Introduction**

**Migraine and Ergotamine**

**Introduction of the Serotonin Antagonists**

**Headache Classification**

**An Account of Auras**

**The Development of Triptans**

**The Trigeminovascular System and Migraine**

**Migraine Genetics**

**Key Outstanding Questions**

**Key Research Groups**

## References

## Additional References

# Chapter 16: Multiple Sclerosis

## Introduction

1916: The Pathological Anatomy of the Lesion in Multiple Sclerosis

1960: Evidence for an Immune Response within the Central Nervous System

1970: An Exemplary Trial of Steroid Treatment of the Acute Relapse

1972: The First Clinical Demonstration of Demyelination

1972: Identifying the Primary Genetic Association for Multiple Sclerosis

1973: Remyelination Is Possible in the CNS

1977: Plotting the Epidemiology of MS

1981: The First Evidence Showing That MS Is Treatable: The End of the Beginning?

1983: A Step towards Increased Diagnostic Accuracy

1988: Surrogate Markers in Life for Disease Activity in MS

## Conclusion

Key Outstanding Questions

Key Research Centres

## References

## Additional References

## **Chapter 17: The Autoimmune Basis for Guillain-Barré Syndrome**

**Introduction**

**What Is Guillain-Barré Syndrome?**

**Describing the Syndrome**

**Defining the Pathology**

**Assessing Treatment**

**Clinical Variants and Neuroimmunology**

**The Mechanism of Antiganglioside**

**Antibody-mediated Nerve Injury**

**Summary and Conclusions**

**Key Outstanding Questions**

**Key Research Centres**

**References**

**Additional References**

## **Chapter 18: Helicobacter pylori, Peptic Ulcers and Gastric Cancer**

**Introduction**

**An Infectious Theory**

**The Human Guinea Pig and Koch's**

**Postulates**

**How Does an Infection in the Antrum Cause**

**Ulcers in the Duodenum? The Gastrin Link**

**What Is the Effect of Helicobacter pylori on**

**Gastric Physiology?**

**A Simple Treatment That Cures Ulcers?**

**The Power of the NIH Consensus**

**Statements**



[The H. pylori Genome](#)

[H. pylori and Gastric Cancer](#)

[H. pylori and the Gastric Cancer versus Duodenal Ulcer Phenotype](#)

[The Role of Host Genetics in Outcome of H. pylori Infection](#)

[Summary and Conclusion](#)

[Key Outstanding Questions](#)

[Key Research Centres](#)

[References](#)

## [Chapter 19: Acute Liver Failure](#)

[Introduction](#)

[Definitions of Acute Liver Failure](#)

[Prognostication in Acute Liver Failure](#)

[Pathophysiology of ALF: Multiple Organ Failure and Covert Tissue Hypoxia](#)

[N-Acetyl Cysteine in ALF: From Clinical Observation to Randomised Controlled Trials](#)

[Ammonia: The Key Player in Hepatic Encephalopathy and Cerebral Oedema](#)

[Conclusion](#)

[Key Outstanding Questions](#)

[Key Research Centres](#)

[References](#)

## [Chapter 20: Haemostasis and Thrombosis](#)

**Introduction**

**The Discovery of Heparin**

**The Discovery of Warfarin**

**The Treatment of Pulmonary Embolism**

**Prevention of Venous Thrombosis**

**Warfarin and Heparin in the Initial**

**Treatment of Thromboembolic Disease**

**Activated Protein C Resistance and the**

**Discovery of the Factor V Leiden Mutation**

**The Introduction of Low Molecular Weight**

**Heparin**

**Mechanical Methods of Preventing**

**Pulmonary Emboli**

**Predicting Venous Thrombosis**

**Conclusion**

**Key Outstanding Questions**

**Key Research Centres**

**References**

## **Chapter 21: The Inherited Disorders of Haemoglobin**

**Introduction**

**Molecular and Cellular Pathology**

**Improvements in the Prevention and**

**Treatment of the Thalassaemias and Sickle**

**Cell Disease**

**Why Are the Inherited Haemoglobin**

**Disorders So Common?**

**Summary**

**Key Outstanding Questions**

[\*\*Acknowledgements\*\*](#)  
[\*\*References\*\*](#)  
[\*\*Additional References\*\*](#)

## [\*\*Chapter 22: Diabetes Therapy and the Prevention of Vascular Damage\*\*](#)

[\*\*Introduction\*\*](#)

[\*\*Urinary Glucose Control and Microvascular Complications in Clinical Practice\*\*](#)

[\*\*Subcutaneous Pumped Insulin: Better Glucose Control in Type 1 Diabetes\*\*](#)

[\*\*A Feasibility Study of Glucose Control and Complications\*\*](#)

[\*\*The Ultimate Type 1 Diabetes Study\*\*](#)

[\*\*Persistent Effects of Glucose Control on Arteriosclerotic Outcomes\*\*](#)

[\*\*Type 2 Diabetes: A Study That Took 20 Years\*\*](#)

[\*\*The Glucose Legacy Effect Wins Again\*\*](#)

[\*\*The Power of Multifactorial Intervention in Type 2 Diabetes\*\*](#)

[\*\*Intensive Glucose Control or Over-Intensive Glucose Control?\*\*](#)

[\*\*Meta-Analysis to the Rescue\*\*](#)

[\*\*Concluding Comment\*\*](#)

[\*\*References\*\*](#)

[\*\*Additional References\*\*](#)

## [\*\*Chapter 23: Rheumatoid Arthritis\*\*](#)

[\*\*Introduction\*\*](#)

**What Is the Tissue Pathology?**

**What Mediates the Systemic Process?**

**How Might Rheumatoid Factors Be Pathogenic?**

**What Is the Basis of Genetic Susceptibility to RA?**

**What Is the Crucial Inflammatory Mediator in RA?**

**Does Smoking Contribute to the Causation of RA?**

**Why Do RA Patients Have Antibodies to Keratin?**

**What New Insights Can Immunohistochemistry Provide?**

**When Does the Immunopathology Begin?**

**Is RA Due to Self-Perpetuating Autoreactive B Cells?**

**Conclusions and Key Outstanding Questions**

**References**

**Additional References**

## **Chapter 24: Osteoarthritis**

**Introduction**

**Risk Factors for Osteoarthritis**

**Focus on Pain**

**Linking Radiological OA and Clinical Symptoms**

**Surgical Treatment of Osteoarthritis**

**Autologous Chondrocyte Implantation: The Future of OA Therapeutics?**

[\*Key Outstanding Questions\*](#)

[\*Key Research Centres\*](#)

[\*References\*](#)

[\*Additional References\*](#)

## [\*Chapter 25: Systemic Vasculitis\*](#)

[\*Introduction\*](#)

[\*Describing the Disease\*](#)

[\*Classification of Vasculitis\*](#)

[\*Aetiology and Pathogenesis\*](#)

[\*Treatment\*](#)

[\*Summary\*](#)

[\*Key Outstanding Questions\*](#)

[\*Key Research Groups\*](#)

[\*References\*](#)

[\*Additional References\*](#)

## [\*Chapter 26: Polycystic Kidney Disease\*](#)

[\*Introduction\*](#)

[\*Autosomal Dominant Polycystic Kidney Disease\*](#)

[\*Describing the Syndrome and Diagnosis of ADPKD\*](#)

[\*Identifying the Genes and Proteins: ADPKD1 Gene and Polycystin-1\*](#)

[\*Identifying the Genes and Proteins: ADPKD2 gene and Polycystin-2\*](#)

[\*Defining the Pathogenesis\*](#)

[\*\*Prospective Treatments\*\*](#)  
[\*\*Autosomal Recessive Polycystic Kidney Disease\*\*](#)  
[\*\*Identifying the Gene and Protein\*\*](#)  
[\*\*Defining the Pathogenesis\*\*](#)  
[\*\*Prospective Treatment\*\*](#)  
[\*\*Summary and Conclusions\*\*](#)  
[\*\*Note\*\*](#)  
[\*\*Key Outstanding Questions\*\*](#)  
[\*\*Key Research Centres\*\*](#)  
[\*\*References\*\*](#)  
[\*\*Additional References\*\*](#)

## [\*\*Chapter 27: Glomerular Disease and the Nephrotic Syndrome\*\*](#)

[\*\*Introduction\*\*](#)  
[\*\*The Beginnings of Clinical Nephrology: Bright's Disease\*\*](#)  
[\*\*Classification of Bright's Disease\*\*](#)  
[\*\*The Nephrotic Syndrome\*\*](#)  
[\*\*Structure, Function and Pathology of the Glomerular Filtration Barrier\*\*](#)  
[\*\*Summary and Conclusions\*\*](#)  
[\*\*Key Outstanding Questions\*\*](#)  
[\*\*Key Research Centres\*\*](#)  
[\*\*References\*\*](#)  
[\*\*Additional References\*\*](#)



## **Chapter 28: Acquired Immunodeficiency Syndrome**

### **Introduction**

#### **The Discovery of AIDS and HIV**

#### **The Origin and Evolution of HIV-1**

#### **Identification of Cellular Entry Receptors and Co-Receptors Required for HIV-1**

### **Infection**

#### **The Course of HIV-1 Infection: From Transmission to the Development of AIDS**

#### **Host Immune Mechanisms Controlling HIV-1 Infection**

#### **Treatment of HIV-1 Infection by Antiretroviral Drugs**

#### **HIV-1 Vaccines: Preventative versus Therapeutic**

### **Conclusion**

#### **Key Outstanding Questions**

#### **Key Research Centres**

### **References**

#### **Additional References**

## **Chapter 29: Transplantation**

### **Introduction**

#### **Identification of Chromosomal Loci**

#### **Encoding Major Histocompatibility Antigens in Mice and Humans**

#### **Tolerance to Transplanted Tissue Can Be Induced Post-natally (skin grafts are**

*rejected by 'cell mediated immunity')*

*Clinical Transplantation of Kidneys Is Feasible*

*Clinical Transplantation of Bone Marrow Creates Chimerism*

*The Thymus Controls the Ability to Reject Grafts and Humoral Responses*

*Mutation Involving Thymus Affecting Ability to Reject Grafts*

*Regulation of Immunity by T Cells*

*T Cell Responses are MHC Restricted - a Central Tenet for All T Cell Responses*

*Repertoire Selection of T Cells in the Thymus Depends on Structural Components of the T Cell Receptor and Self MHC Molecules*

*Key Outstanding Questions*

*Key Research Centres*

*Acknowledgements*

*References*

*Additional References*

## *Chapter 30: Autoimmunity*

*Introduction*

*Is 'Horror Autotoxicus' Possible?*

*Is Collagen Vascular Disease a Systemic Reaction to Dying Self?*

*Might Auto-antibodies Cause Organ-Specific Disease?*

**Can Instability of B Cell Tolerance Be Modeled in Animals?**

**Are B Cell Dynamics as Important as Reactivity?**

**How Can Autoreactive B Cells Get T Cell Help?**

**Does B Cell/T Cell Antigen Discordance Occur In Vivo?**

**What Roles Do Innate Thresholds Play?**

**Are There Genetic Effects on T Cell Tolerance?**

**What Does Therapeutic Depletion of B or T Cells Tell Us?**

**Conclusions**

**Key Outstanding Questions**

**References**

**Additional References**

## **Chapter 31: The Biochemistry of Depression**

**Introduction**

**A Laboratory Test for Depression?**

**Hypersecretion of Cortisol as a State-Independent Marker of Depression**

**Noradrenaline Dysfunction in Depressed Patients**

**Role for Noradrenaline in Depressive Relapse**

**Serotonin and Depression: A Possible Link with Suicide**

[Low Serotonin Function in Depression](#)  
[Detected by Neuroendocrine Challenge](#)  
[PET Imaging of the 5-HT1A Receptor in Depression](#)  
[Tryptophan Depletion Provokes Relapse in Recovered Depressed Patients](#)  
[An Interaction between a Serotonin Genetic Mechanism and Environmental Stress](#)  
[Beyond Monoamines: A Role for GABA and Glutamate in Depression](#)  
[Conclusion](#)  
[Key Questions Remaining](#)  
[References](#)  
[Additional References](#)

## [Chapter 32: Schizophrenia and the Dopamine Hypothesis](#)

[Introduction](#)  
[What Is the Dopamine Hypothesis?](#)  
[Amphetamine-Induced Psychosis](#)  
[Experimental Studies of Amphetamine](#)  
[Discovery of Antipsychotic Drugs](#)  
[Dopamine and Parkinson's Disease](#)  
[Dopamine Blockade and the Efficacy of Antipsychotic Drugs](#)  
[Determination of the Different Classes of Dopamine Receptors](#)  
[Atypical Antipsychotics](#)  
[A Revised Dopamine Theory of Schizophrenia](#)

[\*Imaging Dopamine Receptors\*](#)

[\*Summary and Conclusions\*](#)

[\*Key Outstanding Questions\*](#)

[\*Key Research Centres\*](#)

[\*References\*](#)

## [\*Chapter 33: Alzheimer's Disease\*](#)

[\*Introduction\*](#)

[\*Alzheimer's Original Description of the Disease\*](#)

[\*Loss of Subcortical Neurones from the Basal Nucleus of Meynert\*](#)

[\*The Relationship between the Pathology of Alzheimer's Disease and the Clinical Syndrome\*](#)

[\*Standardising Diagnostic Criteria for Research Studies\*](#)

[\*Revising the NINCDS-ADRDA Criteria\*](#)

[\*The Symptoms of Alzheimer's Disease\*](#)

[\*Cholinesterase Inhibitors as Treatment for AD\*](#)

[\*The Possible Central Role of 'Amyloid'\*](#)

[\*Risk Factor Genes for Alzheimer's Disease: APOE 4\*](#)

[\*Time to Reconsider the Amyloid Cascade Hypothesis? Amyloid Removal from the Brain Does Not Benefit AD Sufferers\*](#)

[\*Key Outstanding Questions\*](#)

[\*Key Research Centres\*](#)

[\*References\*](#)

***Additional References***

***Index***



# Understanding Medical Research

## The Studies That Shaped Medicine

EDITED BY

John A. Goodfellow BM BCh, PhD

Honorary Clinical Academic Fellow  
University of Glasgow  
Glasgow, UK

WITH FOREWORD BY

Sir Liam Donaldson

Chief Medical Officer, 1998-2010  
Department of Health  
London, UK

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2012 © 2012 by John Wiley & Sons, Ltd.

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wileys global Scientific, Technical and Medical business with Blackwell Publishing.

*Registered office:* John Wiley & Sons, Ltd, The Atrium,  
Southern Gate, Chichester, West Sussex,  
PO19 8SQ, UK

*Editorial offices:* 9600 Garsington Road, Oxford, OX4 2DQ,  
UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19  
8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wileyblackwell](http://www.wiley.com/wileyblackwell).

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is

designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

*Library of Congress Cataloging-in-Publication Data*

Understanding medical research : the studies that shaped medicine / edited by

John A. Goodfellow; with foreword by Sir Liam Donaldson.

p.; cm.

Includes bibliographical references and index.

ISBN 9780470654484 (pbk.)

I. Goodfellow, John A.

[DNLM: 1. Biomedical Research. 2. Peer Review, Research. W 20.5]

LC classification not assigned

610.72'4—dc23

2011030825

*To my wife Rosalyn*